Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neosaxitoxin for Brachial Plexus Blockade
NCT03399435Phase 1Terminated
- Sponsor
- Grünenthal GmbH
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of neosaxitoxin in pain (10 arms), sponsored by Grünenthal GmbH. Primary endpoints: Occurrence of dose limiting events at 15 days and Occurrence of adverse events leading to termination at 15 days. Started Jan 2018; status: terminated.
02
Drugs
neosaxitoxin
03
Conditions
pain
Beyond the preview
Go deeper on NCT03399435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399435.